Liselore Loverix

High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

Siel Olbrecht, Pieter Busschaert, Adriaan Vanderstichele et al. · Genome Medicine · 2021 · 180 citations · Full text

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Liselore Loverix, Ignace Vergote, Pieter Busschaert et al. · European Journal of Cancer · 2023 · 31 citations

Medicine, Clinical Trials, Gynecology +11

Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer

Adriaan Vanderstichele, Liselore Loverix, Pieter Busschaert et al. · Gynecologic Oncology · 2022 · 28 citations

Choice Chemotherapy, Medicine, Cancer Management +8

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer

Adriaan Vanderstichele, Pieter Busschaert, C. Landolfo et al. · npj Genomic Medicine · 2022 · 23 citations · Full text

Gynecology, Pathology, Tumor Biology +20

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Eun Young Kang, Joshua Millstein, Gordana Popović et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2021 · 22 citations · Full text

Tumor Biology, Medicine, Pathology +8